Respond to prefers-color-scheme dark in app web views

Follow section front redirects in Spectrum

Enable NLP source in PCS for load testing

Switch off the News Alerts Survey Widget when we have enough responses

Poll to determine if new LUF updates are available

Allows the winning A/B test variant to be turned on without Spectrum deployment

Show infinite scrolling sections in Assembler MultiView

Show option for NLP article summaries in Action Bar

Show NLP summaries collection recirc on article pages

A general feature flag for Recipe Features that aren't yet released

Feature flag for media team features that aren't yet released

Use new Orca video player for preroll plugin in Spectrum

Show the snow tracker (instead of the heat tracker) on Spectrum

Kyle Finnegan’s rare hiccup helps Phillies to a 4-3 win in 10 innings

Joey Gallo returns, but Nats endure another quiet offensive night

Walter Johnson’s jersey from 1920 showdown with Babe Ruth sold at auction

The problem with diversity statements — and what to do about them

Russia shows resilience. There is more to do for Ukraine.

Trump promises tax cuts and fewer rules. CEOs shouldn’t fall for it.

Carolyn Hax: Friends say to break other plans to avoid offending new man

Ask Amy: Should my husband get a say in what I do with my inheritance?

Ask Amy: Can’t a single woman eat alone without interruption?

Would you eat this weird sandwich? Barry Enderwick would. 

She finished chemo then got a medical degree: ‘The dream is real now’

Puppy abandoned with heart-rending note is adopted, named Minerva

The other side of Punta Cana: A crackdown on Haitians

Top White House aide to meet Netanyahu, who is under political pressure

Live updates: Rescuers struggle to find helicopter carrying Iranian president

Blue Origin to fly again as space tourism struggles to get off the ground

Why this company’s biggest fans turned against it

These ISIS news anchors are AI fakes. Their propaganda is real.

In photos: The 149th running of the Preakness Stakes

Book Tour: At home with Amor Towles

Gov. Doug Burgum speaks in support of Trump

‘Never Trump?’ ‘Never Biden’ voters might loom larger.

How Jim Jordan tried to connect the dots on Biden’s $8 million book deal

Lawyer preparation suggests Trump won’t testify in New York trial

Biden’s false claim that inflation was 9 percent when he took office

Did Obamacare ‘massively’ increase the cost of health care?

The world’s coolest hotels want to tell you a story

6 Airbnb red flags to spot before you make a booking mistake

Flying budget airlines might not be as cheap as it seems

Trump trial live updates: Closing arguments set for next week; Cohen resumes testimony

Health

Well+Being

Opinions

Higher Education

Education

https://www.washingtonpost.com/coronavirus/

Coronavirus pandemic

Healthy living, including food, fitness, longevity and mental health

See more coverage in your recommendations

See alerts for Health and Wellness developments

Health & wellness

Tips on living better delivered every Thursday

Well+Being newsletter

Health alerts

Health & Science alerts

Mary Altaffer

The Washington Post is providing this news free to all readers as a public service. Follow this story and more by <a href='https://www.washingtonpost.com/newsletters/health-science-environment-alerts/?method=SURL&location=ART&initiative=FREE'>signing up for health, science, and environment email alerts</a>.

The nearly 17 million Americans who received the one-shot Johnson &amp; Johnson <a href="https://www.washingtonpost.com/coronavirus/" target="_blank" class="contextual_link">coronavirus</a> vaccine are less protected against serious illness and hospitalizations than those who got the Pfizer-BioNTech and Moderna shots, according to federal data released Tuesday.

The latest data suggest Johnson &amp; Johnson recipients should get a booster with one of the messenger RNA vaccines, if they haven’t already done so — and even consider a second messenger RNA booster for the greatest protection. The data come from <a href="https://www.cdc.gov/mmwr/volumes/71/wr/mm7113e2.htm?s_cid=mm7113e2_w" target=_blank>a Centers for Disease Control and Prevention report</a> that analyzed the results of mix-and-match vaccine-and-booster combinations during a four-month period when <a href="https://www.washingtonpost.com/health/2021/11/26/faq-new-variant-omicron/" target=_blank>t</a>he highly transmissible omicron variant was dominant.

Even combining a Johnson &amp; Johnson vaccine with a booster of either Johnson &amp; Johnson, or one of the two messenger RNA vaccines, wasn’t as strong as three shots of the messenger RNA vaccines in preventing emergency room visits or hospitalizations, according to the report.

Shortly after the study’s release, the CDC greenlighted a second booster, either of the Pfizer-BioNTech or Moderna shots, for those who received Johnson &amp; Johnson’s vaccine and booster at least four months ago. It did not formally recommend the second booster but said people may get it if they choose. More than 1.3 million people received the Johnson &amp; Johnson vaccines and booster, according to CDC data.

Brian Monroe

John Farrell

What to know about the omicron variant and subvariant BA.2

The study’s results confirm what health officials and scientists have known for some time based on earlier research. But the report is important because vaccine effectiveness data on the mix-and-match booster strategies in the real world has been limited.

The data, from a 10-state study conducted by independent researchers, may provide clarity amid a confusing stew of data about the single-dose vaccine. It shows that three doses of a messenger RNA vaccine perform the best, while a Johnson &amp; Johnson vaccine followed by a messenger RNA booster shot is next best. Two shots of Johnson &amp; Johnson provide a lower level of protection, with a single shot just 31 percent effective against hospitalization.

“That’s too low, especially in this world where we have access to other things,” said Natalie E. Dean, a biostatistician at Emory University’s Rollins School of Public Health. “One priority is making sure that people who only received one dose [of the Johnson &amp; Johnson vaccine] are aware that they should go and get, preferably, a messenger RNA vaccine.”

The data also suggest a second boost with a messenger RNA vaccine may need to be considered, even for individuals who have received two doses of Johnson &amp; Johnson, said Boghuma Titanji, an infectious-diseases expert at Emory University. “This is not yet a formal recommendation,” Titanji said, “but is something individuals who fall in this category should discuss with their health-care provider.”

The takeaway: “If you can get the messenger RNA vaccine series, and especially get one as a booster, this [study] confirms that is the way to go,” said Jeanne Marrazzo, director of the Division of Infectious Diseases at the University of Alabama at Birmingham.

Experts said the latest CDC study underscores what some experts say is a critical need for clearer recommendations on boosters.

Last fall, the CDC gave Americans eligible for boosters <a href="https://www.washingtonpost.com/health/2021/10/21/mixing-covid-vaccine-booster/" target="_blank">the choice of any one of the three vaccines,</a> regardless of their original shot. In December, however,<a href="https://www.washingtonpost.com/health/2021/12/16/johnson-and-johnson-vaccine-new-data-blood-clots-/" target="_blank"> the agency updated its guidance</a> to recommend people get the messenger RNA vaccines over Johnson &amp; Johnson because of concerns about an extremely rare but potentially fatal blood clot issue.

“Right now, there aren’t recommendations for people who got two doses of J&amp;J to get a third messenger RNA shot,” said William Moss, executive director of the International Vaccine Access Center at the Johns Hopkins Bloomberg School of Public Health. (Those who are moderately to severely immunocompromised are already recommended to get <a href="https://www.washingtonpost.com/health/2022/02/04/coronavirus-booster-shots-immunocompromised/" target=_blank>a third dose.</a>) “The messenger RNA vaccines seem to be providing more protection. … What I’d like to see is a very simple recommendation: that everyone get three doses, and they should be messenger RNA vaccines.”

Several studies have shown the Pfizer and Moderna vaccines remain <a href="https://www.washingtonpost.com/health/2022/03/18/coronavirus-vaccine-worked-against-omicron/" target=_blank>highly effective </a>at preventing the worst outcomes from infections even as protection against less severe illness waned over time.

Although the Johnson &amp; Johnson vaccine provides a lower level of initial protection than the messenger RNA vaccines, the company has pointed to evidence that its vaccine’s protection may not erode as quickly.

A study funded by the division of Johnson &amp; Johnson that developed the vaccine and published in JAMA Network Open found that vaccine effectiveness was stable over six months — 81 percent effective at preventing hospitalization, though it measured a period before the omicron variant’s emergence.

“If there’s something we’ve learned in the pandemic — and it’s not a new lesson — the most informative papers come from people who are independent of the study,” said John P. Moore, a professor of microbiology and immunology at Weill Cornell Medicine.

Moss said it’s important for the public to keep in mind that the goal of vaccination is to prevent severe disease and death. But public messaging became muddled, he said, in part because early studies showed the messenger RNA vaccines provided protection against infection, raising “false expectations.”

It’s natural for the levels of virus-fighting antibodies in the blood to wane over time, Moss added. That’s part of the design of the body’s immune response. “Otherwise our blood would be chock full of antibodies and [blood] wouldn’t be able to flow … and deliver oxygen to the cells,” he said.

The CDC study analyzed data from more than 80,000 emergency room or urgent-care visits, and more than 25,000 hospitalizations among adults with covid-19-like illness in 10 states, from mid-December to March 7, a period that includes the omicron variant surge.

When researchers compared the effectiveness of several vaccine combinations in preventing emergency room or urgent-care visits, they found:

· A single Johnson &amp; Johnson shot offered 24 percent effectiveness.

· Two Johnson &amp; Johnson shots offered 54 percent effectiveness.

· A combination of Johnson &amp; Johnson with one messenger RNA booster offered 79 percent effectiveness.

· Three messenger RNA shots offered 83 percent effectiveness.

Protection against hospitalization, meanwhile, was significantly higher with three doses of the messenger RNA vaccines, which offered 90 percent effectiveness. That compared with:

· A single Johnson &amp; Johnson shot, which offered 31 percent effectiveness.

· Two Johnson &amp; Johnson shots, which offered 67 percent effectiveness.

· A Johnson &amp; Johnson shot with a messenger RNA booster, which offered 78 percent effectiveness.

When the Food and Drug Administration <a href="https://www.washingtonpost.com/health/2021/02/27/johnson-and-johnson-covid-vaccine-fda/" target=_blank>authorized Johnson &amp; Johnson’s vaccine</a> in February 2021 for all adults, many thought the one-and-done approach would make it a tool to vaccinate the world. But last spring, <a href="https://www.washingtonpost.com/health/2021/04/13/why-johnson-johnson-vaccine-paused/" target=_blank>federal officials halted the use of the vaccine</a> for 10 days while they looked into reports of six cases of a rare but potentially life-threatening type of blood clot among the millions of people who had received the shots in the United States. The vaccine’s use waned thereafter, due to supply problems, as well as concerns over the blood clot issue.

Nine deaths — seven women and two men — have been confirmed in connection with the blood clot issue through September. Seven of those patients, who were ages 28 to 62, had underlying medical conditions, including obesity, hypertension and diabetes.

Carolyn Y. Johnson contributed to this report.

Pulitzer Prize for National Reporting for coverage of the war on terrorism, part of national reporting team, 2002

 Robert F. Kennedy journalism award, international print, 1994 

Cornell University, BS in communication

Columbia University, MA in journalism

Lena H. Sun is a national reporter for The Washington Post covering health with a special focus on public health and infectious disease. A longtime reporter at The Post, she has covered the Metro transit system, immigration, education and was a Beijing bureau chief. 